42.8 F
New York
Wednesday, November 30, 2022

Date:

Share:

Aatru Medical Announces FDA Clearance and Commercial Launch of the NPSIMS™ – Negative Pressure Surgical Incision Management System

Related Articles

Huntington Study Group Annual Meeting

Rochester, NY, November 29, 2022 --(PR.com)-- The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its...

Paras Biopharmaceuticals Finland Oy is Highly Recommended for Biologics CDMO – Development / Scale-up & Production of Biologics by Innovative USA Biopharma Company

Oulu, Finland, November 29, 2022 --(PR.com)-- “It is very encouraging when appreciation comes to Paras Biopharmaceuticals, especially from a USA-based company that is very innovative...
Cleveland, OH, August 24, 2021 –(PR.com)– Aatru Medical, LLC (“Aatru”) today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System.

The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electro-mechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed for closed surgical incision applications. The single-use, disposable NPSIMS is easily activated and operates silently during therapy delivery. A patented preassembled dressing provides ease-of-application with exceptional “sealing” capability while providing patient comfort and ergonometric appeal.

The FDA effort was led by Aatru President and Board member Edward Armstrong who leveraged his extensive professional prior experience with NPWT and medical device companies. “This innovative NPWT technology…

Read more…

Popular Articles